Plasma metabolomic profile in nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 60, Issue 3, 2011, Pages 404-413

  Kalhan, Satish C ^a   Guo, Lining ^b   Edmison, John ^a   Dasarathy, Srinivasan ^a   McCullough, Arthur J ^a   Hanson, Richard W ^a,c   Milburn, Mike ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METABOLON INC   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; BUTYRYLCARNITINE; CARNITINE; CYSTEINE; DIPEPTIDE; GLUCOSE; GLUTATHIONE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; HOMOCYSTEINE; LACTIC ACID; LONG CHAIN FATTY ACID; MANNOSE; METHYLBUTYRYLCARNITINE; PHOSPHORYLCHOLINE; PYRUVIC ACID; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; METABOLITE; METABOLOMICS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY LIVER; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

EID: 79951792246     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.03.006     Document Type: Article

References (36)

1. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci 2008;115:141-50.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
3. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci 2009;116:539-64.
4. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52. (Pubitemid 39071617)
5. Gibney MJ, Walsh M, Brennan L, Roche HM, German B, van Ommen B. Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr 2005;682:497-503.
6. Wishart DS. Current progress in computational metabolomics. Brief Bioinform 2007;8:279-93. (Pubitemid 350142618)
7. Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics 2006;6:4716-23. (Pubitemid 44375842)
8. Evans AM, Dehaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/ electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009;81:6656-67.
9. Kleiner DE, Brunt EM, Van NattaM, Behling C, ContosMJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
10. Garcia AJ, Apitz-Castro R. Plasma total homocysteine quantification: an improvement of the classical high-performance liquid chromatographic method with fluorescence detection of the thiol-SBD derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2002;779:359-63. (Pubitemid 35279464)
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. (Pubitemid 15018832)
12. Pennington CR, Ross PE, Bateson MC, Bouchier IAD. Serum bile acids in patient with hyperlipidaemia. J Clin Pathol 1978;31:58-62. (Pubitemid 8293342)
13. Bouchier IAD, Pennington CR. Serum bile acids in hepatobiliary disease. Gut 1978;19:492-6. (Pubitemid 8363907)
14. Brody DH, Leichter L. Clearance tests of liver function. Med Clin North Am 1979;63:621-30. (Pubitemid 9198068)
15. Wei J, Qiu DK, Ma X. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J Dig Dis 2009;10:85-90.
16. Nerfi FO, Severin CH, Valdivieso VD. Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochim Biophys Acta 1978;529:212-23. (Pubitemid 8385208)
17. Uchida K, Takase H, Kadowaki M, Nomura Y, Matsubara T, Takeuchi N. Altered bile acid metabolism in alloxan diabetic rats. Jpn J Pharmacol 1978;29:553-62.
18. Ishida H, Yamashita C, Kuruta Y, Yoshida Y, Noshiro M. Insulin is a dominant suppressor of sterol 12α-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. J Biochem 2000;127:57-64. (Pubitemid 30094094)
19. Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008;14:778-82.
20. Aanlungo S, Miquel JF, Rigotti A, Nervi F. Insulin and cholesterol gallstones: new insights for a complex pathogenic relationship. Hepatology 2008;48:2078-80.
21. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006;25:1419-25.
22. Keitel V, Kubitz R, Häussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol 2008;14:5620-9.
23. Staels B, Fonseca VA. Bile acids and metabolic regulation. Mechanisms and clinical response to bile acid sequestration. Diabetes Care 2009;32:S237-45.
24. Shigesawa T, Sato C, Marumo F. Significance of plasma glutathione determination in patients with alcoholic and non-alcoholic liver disease. J Gastroenterol Hepatol 1992;7:7-11.
25. Altomar E, Vendemiale G, Albano O. Hepatic glutathione content in patients with alcoholic and non alcoholic liver diseases. Life Sci 1988;43:991-8.
26. Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human disease. Arch Physiol Biochem 2007;113:234-58.
27. Dasarathy S, Kasumov T, Edmison JM, Gruca LL, Bennett C, Duenas C, et al. Glycine and urea kinetics in non-alcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol 2009;297:G567-75.
28. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patient with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42. (Pubitemid 40591217)
29. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92. (Pubitemid 32246672)
30. Darmaun D, Smith SD, Sweeten S, Sager BK, Welch S, Mauras N. Evidence for accelerated rates of glutathione utilization and glutathione depletion in adolescents with poorly controlled type 1 diabetes. Diabetes 2005;54:190-6. (Pubitemid 40105112)
31. Puri P, Baillee RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-90. (Pubitemid 350144772)
32. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-26.
33. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OAJ, et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006;49:351-9. (Pubitemid 43185404)
34. Pereira S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes 2008;57:56-63.
35. Gougeon R, Morais JA, Chevalier S, Pereira S, Lamarche M, Marliss EB. Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes. Diabetes Care 2008;31:128-33.
36. Kalhan SC. Fatty acids, insulin resistance and protein metabolism. J Clin Endocrinol Metab 2009;94:2725-7.